Indication Assessment & Prioritization
How we help with Indication Assessment & Prioritization
We help many early-stage clients identify which development pathway is right for their business goals. Halloran helps to identify which assets and indications to prioritize and de-prioritize based on the client’s desired timeline, budget, early preclinical data, and clinical, regulatory, and commercial attributes. As part of this work, a Risk-Benefit Analysis for developing a drug or device in the indications under consideration can be provided as a guide to help mitigate potential pain points during the development.
Related Services
RELATED INSIGHTS
-
Success Planning for an Original NDA / BLA Submission
This comprehensive webinar offers an insightful exploration into the intricate landscape of New Drug Applications (NDAs) and Biologics License Applications (BLAs), elucidating the pivotal regulatory procedures imperative for pharmaceutical companies seeking approval for novel drugs and biologics. Its primary objective is to equip participants with the requisite knowledge and resources essential for navigating the intricate […]
-
Pulling the Thread on FDA’s Master Protocol Draft Guidance
The U.S. Food and Drug Administration’s (FDA) draft guidance, Master Protocols for Drug and Biological Product Development, released on December 21, 2023, provides expanded recommendations on the design and analysis of trials conducted under a master protocol. A master protocol is a protocol designed with multiple substudies, which may have different objectives and involve coordinated […]
-
Are You Planning for Success? Essential Role of the Program Manager
Small life science companies often need to ‘do more with less.’ Leaders of these companies must seek ways to trim costs without sacrificing quality and speed. As you build your development team, you may be tempted to forgo hiring a Program Manager, but that decision may create less-than-desirable results. Leaders of life science companies, especially […]